Harrow Health Maintains Buy Rating, Submits 3 Abstracts to ASCRS Meeting
BTIG reiterated its Buy rating for Harrow Health, with its stock at $35.36 on March 18 and trading 2.16% higher at $34 today. Three scientific abstracts on VEVYE® and ILEVRO® targeting ocular surface and post-cataract treatment were accepted for presentation at the ASCRS 2026 Annual Meeting.
1. BTIG Reiterates Buy Rating
On March 18, BTIG reiterated its Buy rating for Harrow Health, affirming confidence in the company’s ophthalmic disease management focus. At that time, the stock was trading at $35.36, reflecting BTIG’s view on Harrow’s growth trajectory.
2. ASCRS Presentation Highlights
Harrow Health had three scientific abstracts accepted for the ASCRS 2026 Annual Meeting in Washington, D.C., covering studies on ocular surface disease and post-cataract surgery treatments using its products VEVYE® and ILEVRO®. The presentations underscore the company’s commitment to evidence-based innovations.
3. Recent Stock Performance
Harrow Health’s share price stands at $34, up 2.16% or $0.72, with an intraday low of $33.03 and high of $34.87. The company has a market capitalization of $1.27 billion and recorded a trading volume of 634,468 shares.